MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
1.840
+0.010 (0.55%)
At close: Oct 24, 2025, 4:00 PM EDT
1.830
-0.010 (-0.54%)
After-hours: Oct 24, 2025, 7:00 PM EDT
MacroGenics Revenue
MacroGenics had revenue of $22.24M in the quarter ending June 30, 2025, with 105.99% growth. This brings the company's revenue in the last twelve months to $165.50M, up 303.47% year-over-year. In the year 2024, MacroGenics had annual revenue of $149.96M with 155.26% growth.
Revenue (ttm)
$165.50M
Revenue Growth
+303.47%
P/S Ratio
0.70
Revenue / Employee
$485,323
Employees
341
Market Cap
116.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 149.96M | 91.21M | 155.26% |
| Dec 31, 2023 | 58.75M | -93.19M | -61.33% |
| Dec 31, 2022 | 151.94M | 74.49M | 96.19% |
| Dec 31, 2021 | 77.45M | -27.44M | -26.16% |
| Dec 31, 2020 | 104.88M | 40.70M | 63.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MGNX News
- 7 weeks ago - MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities - GlobeNewsWire
- 2 months ago - MacroGenics Appoints Eric Risser as President and Chief Executive Officer - GlobeNewsWire
- 4 months ago - MacroGenics: Working On That Road To Recovery - Seeking Alpha
- 4 months ago - MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement - GlobeNewsWire
- 5 months ago - MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - GlobeNewsWire
- 5 months ago - MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - MacroGenics Announces Date of First Quarter 2025 Financial Results - GlobeNewsWire